Anbio Biotechnology Revenue from Contract with Customer, Including Assessed Tax
Anbio Biotechnology (NNNN) reported Revenue from Contract with Customer, Including Assessed Tax of $8.65 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-04-07
| Period end | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|
| 2025-12-31 | $8.65M 20-F · filed 2026-04-07 |
| 2024-12-31 | $8.19M 20-F · filed 2026-04-07 |
| 2023-12-31 | $6.71M 20-F · filed 2026-04-07 |
| 2022-12-31 | $23.54M 20-F · filed 2025-04-28 |